Scripps 39th Annual New Treatments in Chronic Liver Disease 2025
20.00 $
Description
+ Include: 14 videos Only no PDFs
+ Target Audience: hepatologists, gastroenterologists, internists, transplant specialists
39TH ANNUAL New Treatments in Chronic Liver Disease
March 15-16, 2025 Coronado Island Marriott Coronado, California
This conference will review the latest medications and therapies in liver treatment and transplantation. The results of trials and real-world data using oral drugs to treat chronic viral hepatitis B and C, non-alcoholic fatty liver diseases, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular carcinoma and complications of end-stage liver disease including thrombocytopenia will be reviewed in detail. New Treatments in Chronic Liver Disease is a comprehensive yet concise program for updating physicians on these and other commonly encountered problemsin the treatment of liver diseases.
Educational Objectives
After attending this live activity, participants should be able to:
- Cite new strategies for identifying and managing metabolic liver disease.
- Review updated goals and guidelines for curing Delta Hepatitis, HBV and HCV.
- Discuss potential new treatments for alcohol related liver disease.
- Summarize novel markers and therapies in PBC and PSC.
- Evaluate liver masses and new therapeutic options for HCC.
- Employ strategies for treating and managing ascites and hepatorenal syndrome.
The Scripps 39th Annual New Treatments in Chronic Liver Disease Conference (2025) is best for hepatologists, gastroenterologists, internists, transplant specialists, and allied health professionals who want CME‑accredited updates on the latest therapies, diagnostics, and management strategies for chronic liver disease.
New Treatments in Chronic Liver Disease 2025
Scripps Health
| # | Session Title | Speaker(s) | Runtime |
|---|---|---|---|
| 1 | Use of Surrogate Markers and Algorithms to Identify High-Risk Patients and Optimize Outcomes in MASH | Naim Alkhouri | 28:49 |
| 2 | Lifestyle Recommendations for Clinical Practice | Jennie Luna | 30:41 |
| 3 | Incretins / GLP-1 Receptor Agonists for Patients with MASH and Type 2 Diabetes | Kenneth Cusi | 45:10 |
| 4 | Drug Development for Metabolic-Dysfunction Associated Steatohepatitis (MASH) | Julio Gutierrez | 30:11 |
| 5 | MASLD / MASH Case Presentations | Naim Alkhouri, Julio Gutierrez, Jennie Luna, Kenneth Cusi | 36:58 |
| 6 | New Guidance for Hepatitis B and C | Norah Terrault | 30:33 |
| 7 | All Things Itchy: PBC, PSC, and Pruritus | Christopher Bowlus | 32:08 |
| 8 | Updates on Alcoholic Hepatitis in 2025 | Raymond Lee | 35:13 |
| 9 | Advanced Liver Care – Q & A | Norah Terrault, Julio Gutierrez, Paul Pockros, Christopher Bowlus, Raymond Lee | 18:14 |
| 10 | Approach to Refractory Hepatic Encephalopathy | Sammy Saab | 30:10 |
| 11 | Mock HCC Tumor Board | Ramsey Al-Hakim, Adam Deising, Jonathan Fisher, Kathryn Fowler, Pierre Gholam | 62:34 |
| 12 | Systemic Therapy for Hepatocellular Carcinoma (March 2025 Update) | Pierre Gholam | 27:26 |
| 13 | New Therapies: Getting to HBV (and HDV) Cure | Jordan J. Feld | 55:07 |
| 14 | ESLD, HCC & Transplantation – Q & A | Jordan J. Feld, Paul Pockros, Sammy Saab | 17:23 |
Related products
Critical Care / Emergency Medicine
Intensive Update with Board Review Including COVID-19 in Geriatric and Palliative Medicine 2020